On paper this looks like the one comparison where sermorelin loses on evidence. CJC-1295 has two human trials to sermorelin’s one, both published in a major endocrinology journal, both showing sustained hormone increases. Sermorelin has a single placebo-controlled study in nineteen people.
The trouble is that those two trials studied a version of CJC-1295 that is probably not the one being offered to you, and they measured something narrower than the sermorelin trial did. Both facts point the same way, and neither is obvious from a product page.
At a glance
| Sermorelin | CJC-1295 | |
|---|---|---|
| What the molecule is | The first 29 amino acids of human GHRH, unmodified — the natural signal, shortened [1] | The same 29-amino-acid fragment with four substitutions. The trialed version adds a linker that binds permanently to your own albumin [2] |
| Measured half-life | Short — the reason the analog was built at all, in its own developers’ words [2] | 5.8 to 8.1 days, with DAC [3] |
| Human trials | One, placebo-controlled, nineteen adults, five months [1] | Two, both 2006, both in healthy adults [2] [3] |
| What those trials measured | GH and IGF-1, plus body composition by DXA, skin thickness, insulin sensitivity and a quality-of-life questionnaire [1] | GH and IGF-1. No body-composition, symptom or quality-of-life outcome in either [2] [3] |
| Total published record | 332 PubMed records [4] | 33 PubMed records, many of them doping-detection methods [4] |
| Ever FDA-approved | Twice, as Geref, in 1990 and 1997; both discontinued [5] | Never |
| What you are likely sold | Sermorelin | Usually the version without DAC — the FDA’s own survey of compounders notes that “CJC-1295” in that market means tetra-substituted GRF(1-29) [6] |
The DAC question decides everything else
CJC-1295 was designed to fix one specific problem. Its developers put it plainly: short GHRH infusions do raise GH and IGF-1, “but the short GHRH half-life limits its therapeutic use” [2]. The fix was a drug affinity complex — a linker that binds permanently to circulating albumin after injection, so the molecule stays in the body for days instead of minutes. Measured in healthy adults, the half-life came out at 5.8 to 8.1 days [3].
Strip the DAC off and you have removed the entire point of the molecule. What remains is GHRH(1-29) with four substitutions that improve stability — closer in behavior to sermorelin than to the drug in the trials, and dosed on a similar schedule for the same reason.
Which version is being sold is therefore the whole question, and the FDA has answered it for the compounding market: in its 2024 briefing to the Pharmacy Compounding Advisory Committee, surveying what compounders actually produce, a footnote records that “CJC-1295 is referred to as ‘Tetra-substituted GRF (1-29)’ or CJC without DAC” [6]. If that is what you are offered, the two trials above are not evidence for it.
Two trials, one outcome between them
Both CJC-1295 studies are real, competent and published in the Journal of Clinical Endocrinology and Metabolism. One found dose-dependent GH increases of two- to tenfold lasting six days or more, IGF-1 up 1.5- to threefold for nine to eleven days, and IGF-1 still above baseline for up to 28 days after repeat dosing, with no serious adverse reactions [3]. The other showed that continuous stimulation did not flatten the natural GH rhythm: pulse frequency and magnitude were unchanged while trough GH rose 7.5-fold [2].
That second result is genuinely interesting, because preserving pulsatility is the argument for using a GHRH analog at all rather than growth hormone itself. But notice what neither trial reports: no lean mass, no fat mass, no skin, no sleep, no well-being, no symptom of any kind. Both are pharmacology studies in healthy volunteers. They establish that the drug does what it is supposed to do to two laboratory values, which is exactly the gap between a biomarker and a benefit that the IGF-1 question turns on.
The sermorelin trial is smaller and older and has its own serious limits — nineteen people, one study, never replicated. It did measure body composition, skin thickness, insulin sensitivity and quality of life alongside the hormones [1], and what it found, with the population attached to each result, is a mixed picture rather than a flattering one. Mixed and measured still answers a different question from unmeasured.
Nobody has tested them together
Sermorelin and CJC-1295 appear together in fourteen PubMed records and none is a trial of the combination [4]. That matters because the pair is sold together constantly — what a stack actually contains, and what has been tested goes through the blended products in detail. For this page the point is narrower: choosing between them is a real choice, and combining them is not a documented third option.
How to decide
If you are offered CJC-1295, ask which version. With DAC, you are looking at a weekly-scale drug with two supporting trials and a measured multi-day half-life. Without it, you are looking at a modified GHRH fragment with no human trial of its own, on a dosing schedule much like sermorelin’s. Sellers rarely make the distinction unprompted, and it is the difference between two different evidence bases.
If the honest answer is “without DAC,” then the two options are closer than the trial counts suggest, and sermorelin has the better-documented history of the pair — a discontinued FDA approval behind it, and the one trial that looked past the bloodwork. Neither is a settled treatment. The questions worth asking a prescriber apply to both, and the third molecule usually in the same conversation works by a different mechanism again.